Top Stories
Latest Coverage
Rituximab Procurement Options: Different Budget Solutions from Originator Drugs to Biosimilars
In the field of hematologic oncology, Rituximab is a classic targeted biologic with a long history of clinical use. S...
In the field of hematologic oncology, Rituximab is a classic targeted biologic with a long history of clinical use. S...
How to Submit a Medicine Request? A Guide to DengYue Pharmacy's Online Medicine Request Service
As the internet and digital services continue to become an increasingly important part of healthcare and the pharmace...
As the internet and digital services continue to become an increasingly important part of healthcare and the pharmace...
NF1-Associated Plexiform Neurofibroma: Treatment Needs and the Latest Advances in Adult Patients
Neurofibromatosis type 1 (NF1) is a genetic disorder that can manifest from childhood, and some patients develop plex...
Neurofibromatosis type 1 (NF1) is a genetic disorder that can manifest from childhood, and some patients develop plex...
Oral Medications for Prostate Cancer: How Can Patients Achieve More Structured Home-Based Management?
As prostate cancer treatment continues to evolve, some patients no longer need to rely entirely on treatment administ...
As prostate cancer treatment continues to evolve, some patients no longer need to rely entirely on treatment administ...
2026 CSCO Guideline Includes Nolgileucel: A Key Development for China-Originated TIL Therapy
On September 17, 2026, the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) opened in Jinan, Ch...
On September 17, 2026, the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) opened in Jinan, Ch...
Global PD-1 Competition Heats Up: China Emerges as a Major Force in Cancer Immunotherapy
Over the past decade, PD-1/PD-L1 immune checkpoint inhibitors have reshaped the landscape of cancer treatment. Keytru...
Over the past decade, PD-1/PD-L1 immune checkpoint inhibitors have reshaped the landscape of cancer treatment. Keytru...
